Cetuximab biosimilar (Reliance Life Sciences)

西妥昔单抗生物类似药 (Reliance Life Sciences)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCetuximab biosimilar (Reliance Life Sciences)

Drug Alias NameCetuximab (Reliance Life Sciences)西妥昔单抗生物仿制药 (Reliance Life Sciences)Cetuximabum (Reliance Life Sciences)R-TPR-033

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar

Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists

TargetsEpidermal growth factor receptor erbB1

Therapy Area/IndicationsHead and Neck Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

China Registration ClassN/A

Active CompaniesN/A

Active IndicationsN/A

Inactive IndicationsHead and Neck Neoplasms

ATC CodeL01XC06